Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tezosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.99 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tezosentan SCHEMBL29194446 | 1.00 | EDNRA (0.99) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4525 | 0.99 | EDNRA (1.00) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29565931 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29706388 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1652657 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| Tezosentan SCHEMBL387772 | 0.89 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL1230886 | 0.89 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4524 | 0.88 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL29409604 | 0.88 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL6963555 | 0.88 | EDNRA (0.79) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169881-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-10 | — | — | US | disclosed |
| EP-3716979-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | Idorsia Pharmaceuticals Ltd (CH) | 2020-10-07 | — | — | EP | disclosed |
| EP-1813611-B1 | 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-1724278-B1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| CN-101657471-B | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP | 2013-07-03 | — | — | CN | disclosed |
| US-8324176-B2 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| EP-1548024-B1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-06-06 | — | — | EP | disclosed |
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-20040116357-A1 | For prophylaxis and therapy of hyperglycemia such as diabetes, diabetic complications or obesity | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1415983-A1 | 5-AMIDINO-N-(2-AMINOPHENETHYL)-HYDROXYBENZENESULFONAMIDE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| CN-1492873-A | Glucopyranosyloxypyrazole derivatives and their use in medicaments | ����ҩƷ��ҵ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1405859-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1400529-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-1367060-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1364958-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | EDNRA 826/4885EDNRB 629/4885 |
| US-20210169881-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | SLC5A2, SLC5A1, GLP1R | EDNRA 6/4885EDNRB 9/4885 |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, UGGT1 | EDNRA 3888/4885EDNRB 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.